Literature DB >> 12060850

Bovine enterovirus as an oncolytic virus: foetal calf serum facilitates its infection of human cells.

M Smyth1, A Symonds, S Brazinova, J Martin.   

Abstract

Many viruses have been investigated for their oncolytic properties and potential use as therapeutic agents for cancer treatment. Most of these replication-competent viruses are human pathogens. We investigated the oncolytic properties of an animal virus which is non pathogenic for both its natural host and humans. Bovine enterovirus has previously been shown to exhibit a very wide tissue tropism for cell types in vitro. We compare the ability of bovine enterovirus to replicate in and to cause cytopathic effect in freshly isolated human monocytes and monocyte derived macrophages with the monocyte-like U937 tumour cell line. We also include the adherent ZR-75-1 human breast cancer cell line. We have also carried out infections of bovine enterovirus in the presence and in the absence of serum of bovine origin. Our study shows that the virus will replicate in and produce cytopathic effect in the U937 and ZR-75-1 cell types to the same extent as the cells (BHK-21) in which the virus is routinely propagated. We believe bovine enterovirus to be a worthwhile candidate for further study as an anti-tumour agent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12060850     DOI: 10.3892/ijmm.10.1.49

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  9 in total

1.  Cytolytic replication of echoviruses in colon cancer cell lines.

Authors:  Stina Israelsson; Nina Jonsson; Maria Gullberg; A Michael Lindberg
Journal:  Virol J       Date:  2011-10-14       Impact factor: 4.099

Review 2.  Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products.

Authors:  Carol Marcus-Sekura; James C Richardson; Rebecca K Harston; Nandini Sane; Rebecca L Sheets
Journal:  Biologicals       Date:  2011-10-13       Impact factor: 1.856

Review 3.  Developing Picornaviruses for Cancer Therapy.

Authors:  Cormac McCarthy; Nadishka Jayawardena; Laura N Burga; Mihnea Bostina
Journal:  Cancers (Basel)       Date:  2019-05-16       Impact factor: 6.639

4.  Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing.

Authors:  Andreas Berting; Maria R Farcet; Thomas R Kreil
Journal:  Biotechnol Bioeng       Date:  2010-07-01       Impact factor: 4.530

Review 5.  Non-human viruses developed as therapeutic agent for use in humans.

Authors:  Danijela Koppers-Lalic; Rob C Hoeben
Journal:  Rev Med Virol       Date:  2011-05-11       Impact factor: 6.989

Review 6.  Oncolytic viruses in cancer therapy.

Authors:  Markus J V Vähä-Koskela; Jari E Heikkilä; Ari E Hinkkanen
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

7.  Isolation and Identification of Type F Bovine Enterovirus from Clinical Cattle with Diarrhoea.

Authors:  Chengyuan Ji; Yao Zhang; Ruini Sun; Jiale Ma; Zihao Pan; Huochun Yao
Journal:  Viruses       Date:  2021-11-04       Impact factor: 5.048

8.  Isolation and Identification of Two Clinical Strains of the Novel Genotype Enterovirus E5 in China.

Authors:  Chengyuan Ji; Yao Zhang; Ruini Sun; Zihao Pan; Jiale Ma; Huochun Yao
Journal:  Microbiol Spectr       Date:  2022-06-02

9.  Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.

Authors:  P Seshidhar Reddy; Kevin D Burroughs; Laura M Hales; Shanthi Ganesh; Brian H Jones; Neeraja Idamakanti; Carl Hay; Shawn S Li; Kristine L Skele; Ann-Jeanette Vasko; Jingping Yang; D Neil Watkins; Charles M Rudin; Paul L Hallenbeck
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.